Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -38.25% is 30% below its 5-year average of -29.50%, near the low end of its 5-year range (-50.18%–-4.28%).
90.73% below its 12-month average of -20.05%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -12.04%.
RETURN ON ASSETS (ROA)
-38.25%
RETURN ON ASSETS (ROA) AVG TTM
-20.05%
RETURN ON ASSETS (ROA) AVG 3Y
-26.23%
RETURN ON ASSETS (ROA) AVG 5Y
-29.50%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-90.73%
CURRENT VS 3Y AVG
-45.84%
CURRENT VS 5Y AVG
-29.66%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-28.05%
median of 560 covered companies
CURRENT VS SECTOR MEDIAN
-36.39%
vs the sector median at left
Century Therapeutics, Inc.
Market Cap
$260.75M
Return on Assets (ROA)
-38.25%
TTM Avg
-20.05%
3Y Avg
-26.23%
5Y Avg
-29.50%
Market Cap
$260.09M
Return on Assets (ROA)
-2.06%
TTM Avg
-16.77%
3Y Avg
-17.09%
5Y Avg
-12.28%
Market Cap
$262.00M
Return on Assets (ROA)
-134.38%
TTM Avg
-47.50%
3Y Avg
-42.91%
5Y Avg
-40.55%
Market Cap
$258.73M
Return on Assets (ROA)
-34.24%
TTM Avg
-52.06%
3Y Avg
-53.17%
5Y Avg
-44.53%
Market Cap
$264.73M
Return on Assets (ROA)
-37.07%
TTM Avg
-27.27%
3Y Avg
-64.53%
5Y Avg
-52.03%
Market Cap
$265.63M
Return on Assets (ROA)
-29.15%
TTM Avg
-33.84%
3Y Avg
-33.85%
5Y Avg
-31.54%
Market Cap
$266.50M
Return on Assets (ROA)
-35.96%
TTM Avg
-58.88%
3Y Avg
-82.10%
5Y Avg
-113.46%
Market Cap
$251.33M
Return on Assets (ROA)
-49.04%
TTM Avg
-75.08%
3Y Avg
-74.95%
5Y Avg
-71.96%
Market Cap
$274.05M
Return on Assets (ROA)
-128.66%
TTM Avg
-214.31%
3Y Avg
-145.75%
5Y Avg
-133.94%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | $260.75M | -38.25% | -20.05% | -26.23% | -29.50% |
| Anika Therapeutics, Inc. (ANIK)vs › | $260.09M | -2.06% | -16.77% | -17.09% | -12.28% |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $262.00M | -134.38% | -47.50% | -42.91% | -40.55% |
| Lexeo Therapeutics, Inc. Common Stock (LXEO)vs › | $258.73M | -34.24% | -52.06% | -53.17% | -44.53% |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $264.73M | -37.07% | -27.27% | -64.53% | -52.03% |
| AC Immune S.A. (ACIU)vs › | $265.63M | -29.15% | -33.84% | -33.85% | -31.54% |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $266.50M | -35.96% | -58.88% | -82.10% | -113.46% |
| Invivyd, Inc. (IVVD)vs › | $251.33M | -49.04% | -75.08% | -74.95% | -71.96% |
| Indaptus Therapeutics, Inc. (INDP)vs › | $274.05M | -128.66% | -214.31% | -145.75% | -133.94% |
| Aurora Cannabis Inc. (ACB)vs › | $275.02M | -18.18% | -10.00% | -29.10% | -54.94% |
ROA
-38.3%
ROE
-47.3%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -4.28% |
| 2024-12-31 | -35.83% |
| 2023-12-31 | -37.89% |
| 2022-12-31 | -26.91% |
| 2021-12-31 | -21.91% |
| 2020-12-31 | -50.18% |
| 2019-12-31 | -269.28% |
